Introduction/Background Ovarian malignant germ cell tumors (OMGCT’s) are derived from primitive germ cells of the embryonic gonad and they are heterogenous tumors. OMGCT should be investigated separately from other tumors for its association to long-term survival, different pathways and biological characteristics. This study was performed to evaluate the clinical and pathological characteristics of patients who were followed up for OMGCT in the last twenty-five years in our clinic. We also aimed to investigate prognostic parameters and the effect of findings on survival rates.
Methodology One hundred and fifteen patients with OMGCT, treated and followed-up between April 1992 and November 2017 were included to this study. Clinical characteristics, operative information, pathologic findings, treatment and follow-up data of the patients were gathered from medical records. The parameters on survival was investigated. Survival analysis were performed using Kaplan - Meier test. Overall survival (OS) and Disease Free Survival (DFS)’s statistically significance was evaluated with Log-Rank test. Reproductive outcomes were analyzed.
Results The average age of patients were 27.5±14.3. Mean follow-up time was 71 months. Approximately 61 (53%) of patients was Stage 1. Complete staging surgery (CSS) was performed 60 patients. Fertility-sparing surgery (FSS) was performed 55 patients. Nineteen (34.5%) of the FSS patients had pregnancy and 15 of them had live births. Poor prognostic factors were suboptimal cytoreduction, advanced stage disease, poor differentiation, metastasis, mixed germ cell histological type, co-morbidity of patients. Factors affecting disease-free survival (DFS) in multivariate analyzes are advanced stage, mixed germ cell histology, and suboptimal cytoreduction. The 5-year survival rate of the 115 patients was 74%.
Conclusion Both DFS and OS period of mixed germ cell ovarian tumors were shown to be significantly lower than other histologic types. The high pregnancy rates after fertility surgery are hopeful for patients.
Disclosure Nothing to disclose.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.